Characteristics, outcomes and treatment patterns in acute myeloid leukemia patients 60 years or older in Colombia: a RENEHOC-PETHEMA study

被引：0

作者：

Sossa-Melo, Claudia ^{[1
,2
]}

Abello-Polo, Virginia ^{[3
]}

Salazar, Luis A. ^{[1
,2
]}

Pena, Angela M. ^{[2
]}

Luna-Gonzalez, Maria ^{[1
,26
]}

Cuervo-Lozada, Diana ^{[27
]}

Quintero-Vega, Guillermo E. ^{[5
,28
]}

Daza, Jorge ^{[4
]}

Omana-Orduz, Olga Paola ^{[6
,29
]}

Mantilla, William ^{[7
,31
]}

Perdomo, Ivan ^{[8
]}

Galvez, Kenny ^{[9
]}

Diaz-Correa, Laura Maria ^{[9
]}

Guerrero-Burbano, Paola Andrea ^{[10
]}

Herrera, Juan Manuel ^{[10
]}

Idrobo, Henry ^{[11
,12
]}

Gaviria, L. M. ^{[13
,30
]}

Correa-Correa, Mario Ernesto ^{[14
,15
]}

Lobaton, Jose ^{[16
]}

Bermudez, Carlos Daniel ^{[17
]}

Pedraza-Morales, Julian Eduardo ^{[18
]}

Serrano-Casas, Juan Carlos ^{[19
]}

Jaramillo, Francisco ^{[20
]}

Gomez, Rigoberto ^{[21
]}

Rosales, Carmen ^{[22
]}

Solano, Maria Helena ^{[27
]}

Varon, Carlos ^{[23
]}

Rodriguez-Veiga, Rebeca ^{[24
]}

Martinez-Cuadron, David ^{[24
]}

Montesinos, Pau ^{[24
,25
]}

机构：

[1] Univ Autonoma Bucaramanga, Fac Hlth Sci, Floridablanca, Colombia

[2] Fundac Oftalmol Santander FOSCAL, Hematol & Hematopoiet Stem Cell Transplantat Unit, Torre C Piso 9 Consultorio 910,Calle 158 20-95, Floridablanca, Santander, Colombia

[3] Lymphoma Myeloma Ctr Tratamiento & Invest Canc Lui, Clin Func Unit Leukemia, Bogota, Colombia

[4] Ctr Tratamiento & Invest Canc Luis Carlos Sarmient, Hematol Unit, Bogota, Colombia

[5] Fdn Santa Fe Bogota, Bogota, Colombia

[6] Ctr Tratamiento Invest Canc Luis Carlos Sarmiento, Funct Unit Leukemia Lymphoma & Myeloma, Bogota, Portugal

[7] Fdn Cardioinfantil, Inst Cardiol, Bogota, Colombia

[8] Clin Los Nogales, Hematol Unit, Bogota, Colombia

[9] Hosp Pablo Tobon Uribe, Hematol Unit, Medellin, Colombia

[10] Clin Imbanaco, Hematologist Canc Unit, QuironSalud, Cali, Colombia

[11] Ctr Med Julian Coronel, Hematol Unit, Cali, Colombia

[12] Univ Valle, Fac Hlth Sci, Cali, Colombia

[13] Hosp Univ San Vicente Fdn, Hematol Unit, Medellin, Colombia

[14] Clin Nuestra Senora Remedios, Hematol Unit, Cali, Colombia

[15] Pontificia Univ Javeriana, Fac Hlth Sci, Cali, Colombia

[16] CECANCOL, Ctr Cancerol Colombia, Monteria, Colombia

[17] Ctr Invest Oncol, Hematol Dept, Clin San Diego, Bogota, Colombia

[18] Clin Colsubsidio 127, Hematol Serv, Bogota, Colombia

[19] Clin Cancerol Norte Santander, Hematol Serv, Cucuta, Colombia

[20] Fdn Valle Lili, Hematol Unit, Cali, Colombia

[21] IDC Hematooncol SA, Hematol Serv, Cali, Colombia

[22] Soc Oncol & Hematol Cesar SOHEC, Hematol Unit, Valledupar, Colombia

[23] Unidad Hematol Especializada, Hematol Serv, Cucuta, Colombia

[24] Hosp Univ Politecn La Fe, Unidad Coloproctologia, Valencia, Spain

[25] Univ Valencia, Fac Med, Valencia, Spain

[26] Programa Tratamiento Enfermedades Hematooncol Sant, Floridablanca, Colombia

[27] Hosp San Jose, FUCS, Hematol Unit, Bogota, Colombia

[28] Univ Los Andes, Fac Med, Bogota, Colombia

[29] Luis Carlos Sarmiento Angulo Canc Treatment & Res, Direct Res & Educ, Cra 14 169-49, Bogota, Colombia

[30] Univ Antioquia, Fac Med, Medellin, Colombia

[31] Ctr Tratamiento Invest Canc Luis Carlos Sarmiento, Breast Canc Unit, Bogota, Colombia

来源：

ANNALS OF HEMATOLOGY | 2025年 / 104卷 / 01期

关键词：

Acute myeloid leukemia; Treatment outcomes; Elderly patients; Overall survival; WORLD-HEALTH-ORGANIZATION; CLASSIFICATION; AML; AGE; NEOPLASMS; REVISION; ADULTS;

D O I：

10.1007/s00277-024-06120-0

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

There is a limited information available on the clinical characteristics, treatment patterns and outcomes on older patients diagnosed with Acute Myeloid Leukemia (AML) in Latin-America. This multicenter retrospective study analyzed 269 patients over 60 years of age diagnosed with AML in Colombia, using data from RENEHOC-PETHEMA registry, from 2009 to 2023. The median age at diagnosis was 70 years (Range:60-98), 55% were men, 61% had an ECOG < 2, and 75.5% had de novo AML. FLT3-ITD or NPM1 mutations were performed in 23.4% and 15.6% patients, and detected in 14.3% and 16.7% of cases, respectively. Treatment included intensive chemotherapy (IC) (36.8%), Low-Intensity Regimen Based on Low-Dose Cytarabine (LDAC-based) (12.6%), hypomethylating agents (HMAs, with/without venetoclax) (35.3%), and supportive care (15.2%). The overall survival (OS) rate was 35.2% at 1 year and 5.6% at 5 years (13.7% for IC, 9.4% for LDAC-based, and 0% for other treatments); with median OS of 8.2 months (10.6 months after IC, 8.8 months after non-IC, 8.9 months after azacitidine/decitabine, 8.2 months after azacitidine-venetoclax, and 1.9 months with supportive care). Only 1.5% of patients underwent a transplant in the first line. The Leukemia-free survival (LFS) rate was 45.8% at 1-year and 13.7% at 5-years (22.4% for IC, 9.4% and 0% for other treatments); with median LFS of 9.5 months (17.3 months after IC, 7.4 months after LDAC-based, and 10.8 months after HMA). This study provides new insights into the management of patients in Colombia, highlighting the need for a highly individualized approach in treating AML in elderly patients.

引用

页码：369 / 381

页数：13

共 50 条

[21] An analysis of treatment choices for acute myeloid leukemia in patients 60 years and older from the University of Duesseldorf AML/MDS database
Klaerner, Viola
Kuendgen, Andrea
De Porre, Peter
Hildebrandt, Barbara
Haas, Rainer
Gattermann, Norbert
Germing, Ulrich
BLOOD, 2007, 110 (11) : 163B - 163B
[22] The who, how and why: Allogeneic transplant for acute myeloid leukemia in patients older than 60 years
Wall, Sarah A.
Devine, Steven
Vasu, Sumithira
BLOOD REVIEWS, 2017, 31 (06) : 362 - 369
[23] Nonmyeloablative stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia in patients 60 years or older
Gupta, V
Daly, A
Lipton, JH
Hasegawa, W
Chun, C
Kamel-Reid, S
Tsang, R
Yi, QL
Minden, M
Messner, H
Kiss, T
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2005, 11 (10) : 764 - 772
[24] PATTERNS OF RESCUE TREATMENT IN PATIENTS WITH ACUTE MYELOID LEUKEMIA TREATED IN THE FIRST LINE WITH AZACITIDINE AND DECITABIN: RESULTS OF THE PETHEMA AML REGISTRY
Jorge, Labrador
David, Martinez-Cuadron
Adolfo, De la Fuente
Rebeca, Rodriguez-Veiga
Josefina, Serrano
Mar, Tormo
Jose-Antonio, Perez-Simon
Fernando, Ramos
Teresa, Bernal
Maria, Lopez-Pavia
Fernanda, Trigo
Maria-Pilar, Martinez-Sanchez
Juan-Ignacio, Rodriguez-Gutierrez
Carlos, Rodriguez-Medina
Cristina, Gil
Daniel, Garcia-Belmonte
Susana, Vives
Maria-Angeles, Foncillas-Garcia
Manuel, Perez-Encinas
Andres, Novo
Isabel, Recio
Gabriela, Rodriguez-Macias
Juan-Miguel, Bergua
Miguel-Angel, Sanz
HAEMATOLOGICA, 2021, 106 (10) : 218 - 218
[25] Outcomes of older patients aged 60 to 70 years undergoing reduced intensity transplant for acute myeloblastic leukemia: results of the NCRI acute myeloid leukemia 16 trial
Russell, Nigel H.
Hills, Robert K.
Thomas, Abin
Thomas, Ian
Kjeldsen, Lars
Dennis, Mike
Craddock, Charles
Freeman, Sylvie
Clark, Richard E.
Burnett, Alan K.
HAEMATOLOGICA, 2022, 107 (07) : 1518 - 1527
[26] Treatment Patterns and Survival Outcomes for Very Elderly Patients with Acute Myeloid Leukemia: A National Cancer Database Study
Zhang, Tina Y.
Ge, Alex Y.
Epstein, Mara Meyer
Patel, Shyam Ajay
BLOOD, 2024, 144 : 2418 - 2419
[27] Treatment intensity in older patients with acute myeloid leukemia.
Büchner, T
ZEITSCHRIFT FUR GERONTOLOGIE UND GERIATRIE, 1999, 32 (02): : 291 - 291
[28] Novel Strategies in the Treatment of Older Patients with Acute Myeloid Leukemia
Kadia, Tapan
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S51 - S53
[29] Older Patients with Acute Myeloid Leukemia Deserve Individualized Treatment
de Leeuw, David C.
Ossenkoppele, Gert J.
Janssen, Jeroen J. W. M.
CURRENT ONCOLOGY REPORTS, 2022, 24 (11) : 1387 - 1400
[30] Changing Paradigms in the Treatment of Acute Myeloid Leukemia in Older Patients
Bazinet, Alexandre
Kadia, Tapan M.
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2022, 20 (01) : 37 - 46

← 1 2 3 4 5 →